Emergent BioSolutions Inc. (EBS)
| Market Cap | 439.08M +47.2% |
| Revenue (ttm) | 676.80M -29.9% |
| Net Income | -8.60M |
| EPS | -0.21 |
| Shares Out | 51.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 439,665 |
| Open | 8.83 |
| Previous Close | 8.95 |
| Day's Range | 8.34 - 8.95 |
| 52-Week Range | 5.31 - 14.06 |
| Beta | 2.33 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+41.01%) |
| Earnings Date | Apr 30, 2026 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for EBS stock is "Strong Buy" and the 12-month stock price target is $12.0.
News
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Emergent BioSolutions Earnings Call Transcript: Q1 2026
Q1 2026 revenue and EBITDA exceeded expectations, driven by strong MCM and naloxone performance, international expansion, and operational efficiency. Debt reduction, refinancing, and new partnerships strengthened the financial position, with full-year guidance maintained.
Emergent BioSolutions Reports First Quarter 2026 Financial Results
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2026.
Emergent BioSolutions receives Singapore regulatory approval for ACAM2000
Emergent BioSolutions (EBS) announced that Singapore’s Health Sciences Authority has approved an expanded indication for ACAM2000 to include prevention of mpox disease in adults determined to be at hi...
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for AC...
Emergent BioSolutions Transcript: AGM 2026
The meeting highlighted significant financial improvements in 2025, including higher EBITDA, reduced debt, and expanded product lines. All shareholder proposals passed, and strategic plans focus on growth, innovation, and international expansion.
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical develop...
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support th...
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
WINNIPEG, Manitoba, April 29, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced it is teaming up with professional baseball player Davis Schneider to break down the stigma ar...
Emergent BioSolutions reports Imojev manufacturing pact with Substipharm
Emergent BioSolutions (EBS) announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5M to support drug substance manufacturing for its Japanese Encephalitis v...
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximat...
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan Refinancing extends maturities, reduces inte...
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m.
Emergent BioSolutions teams with British Columbia on Take-Home Naloxone Program
Emergent BioSolutions (EBS) announced that it has partnered with the B.C. Provincial Health Services Authority to supply Narcan Nasal Spray for the province’s Take-Home Naloxone Program. This order fo...
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCA...
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency New ...
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that m...
Emergent BioSolutions announces over $60M in government contract awards
Emergent BioSolutions (EBS) announced it has secured a contract award valued at approximately $54M to deliver CNJ-016 to the Administration for Strategic Preparedness and Response, or ASPR, part of th...
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016®...
Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.
The first severe case of the virus has been detected in New York.
Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Emergent BioSolutions (EBS) to $12 from $15 and keeps a Buy rating on the shares following the earnings miss. The firm cites…
Emergent BioSolutions appoints Fowler to board of directors
Emergent BioSolutions (EBS) announced the appointment of John Fowler, Jr. to its board of directors effective March 1, 2026. Fowler brings more than three decades of leadership experience across the…
Emergent BioSolutions appoints Fowler to board of directors
Emergent BioSolutions (EBS) announced the appointment of John Fowler, Jr. to its board of directors effective March 1, 2026. Fowler brings more than three decades of leadership experience across the…
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D.
Emergent BioSolutions sees FY26 revenue $720M-$760M, consensus $809.4M
The company also forecasts FY26 adjusted net income of $25M-$45M and adjusted EBITDA of $135M-$155M. “Our team remains focused on long-term sustainable value and achieving our vision of enabling sever...